Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom Sells Bench-top MassArray Unit to Australia s Garvan Institute

NEW YORK, Sept. 16 (GenomeWeb News) - Sequenom has sold one of its MassArray Compact systems to the Garvan Institute of Medical Research in Sydney, Australia.

The institute intends to perform SNP discovery, SNP-genotyping, and gene-expression studies on the system, Sequenom said. Specifically, researchers at the center plan to use the MassARRAY instrument to help them develop new genetic markers for cancer risk, diagnosis, disease progression, and therapeutic responsiveness.

Financial terms of the sale were not disclosed.

Sequenom began selling the desktop MassArray one year ago, according to Pharmacogenomics Reporter, GenomeWeb News' sister publication. The product, which is 73 percent smaller than the full-size system and costs around $285,000, takes 45 minutes to run a single plate, according to a company spokesperson. The standard MassArray platform takes around 25 minutes and costs around $500,000.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.